TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT06091579
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral placebo inhalation using a Plastiape capsule-based dry powder inhaler.
Study: NCT04330183
Drug: Normal Saline
Normalized name: Normal Saline Flush
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3cc of normal saline
Study: NCT02324985
Drug: S-Ibuprofen Topical Gel 5%
Approvals — FDA: no, EMA: no, PMDA: no
Description: S-Ibuprofen Topical Gel 5% applied every 6 hours
Study: NCT00562627
Drug: ketorolac
Normalized name: Ketorolac
DrugBank: Ketorolac (DB00465)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: intraoperative and 1. postoperative day
Study: NCT00562627
Drug: fentanyl
Normalized name: Fentanyl
DrugBank: Fentanyl (DB00813)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: continuous postoperatively
Study: NCT00597701
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo
Study: NCT01107418
Drug: RO5185426
Approvals — FDA: no, EMA: no, PMDA: no
Description: dosage b) orally twice daily, days 1-15 (morning dose)
Study: NCT01107418
Drug: RO5185426
Approvals — FDA: no, EMA: no, PMDA: no
Description: dosage c) orally twice daily, days 1-15 (morning dose)
Study: NCT01107418
Drug: RO5185426
Approvals — FDA: no, EMA: no, PMDA: no
Description: dosage d) orally twice daily, days 1-15 (morning dose)
Study: NCT01107418
Drug: RO5185426
Approvals — FDA: no, EMA: no, PMDA: no
Description: 960 mg orally twice daily, from day 22 onward
Study: NCT01107418
Drug: RO5185426
Approvals — FDA: no, EMA: no, PMDA: no
Description: dosage a) orally twice daily, days 1-15 (morning dose)
Study: NCT00017238
Drug: KRN5500
Approvals — FDA: no, EMA: no, PMDA: no
Description: Given IV
Study: NCT01155219
Drug: Geltim LP 1 mg/g
Approvals — FDA: no, EMA: no, PMDA: no
Description: one drop in the conjunctival sac of each eye in the morning (84 days).
Study: NCT00460369
Drug: artemether-lumefantrine
Normalized name: artemether-lumefantrine
Approvals — FDA: no, EMA: no, PMDA: no
Description: tablets 20/120 mg~* 1 tablet twice daily for 3 days below 15 kg of bodyweight~* 2 tablets twice daily for 3 days below 24 kg of bodyweight~* 3 tablets twice daily for 3 days below 35 kg of bodyweight
Study: NCT02886689
Drug: TNF-alpha antagonist and other biotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00421785
Drug: Oral N-Acetylcysteine 1200 mg x 2/day for 4 weeks.
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00185991
Drug: gentamicin
Normalized name: Gentamicin
DrugBank: Gentamicin (DB00798)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Daily gentamicin (5 mg/kg intravenously, then placebo doses IV after 8 and 16 hours).~Eight hour gentamicin (2 mg/kg intravenously, then 1.5 mg/kg IV after 8 and 16 hours).
Study: NCT02889692
Drug: YiQiFang
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prescriptions formulated into TCM granules origin from Professor Liu Jia-xiang in Longhua hospital. Package of granules is made into three types with functions such as benefiting Qi, benefiting Yin and detoxication recipe.~YiQiFang: Patients with Qi deficiency syndrome are administered two packages of each benefiting Qi and detoxication recipe, four packages, twice a day, until progression or unacceptable.
Study: NCT02889692
Drug: YangYinFang
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prescriptions formulated into TCM granules origin from Professor Liu Jia-xiang in Longhua hospital. Package of granules is made into three types with functions such as benefiting Qi, benefiting Yin and detoxication recipe.~YangYinFang: Patients with Yin deficiency syndrome are administered two packages of each benefiting Yin and detoxication recipe, four packages, twice a day, until progression or unacceptable.
Study: NCT02889692
Drug: YiQiYangYinFang
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prescriptions formulated into TCM granules origin from Professor Liu Jia-xiang in Longhua hospital. Package of granules is made into three types with functions such as benefiting Qi, benefiting Yin and detoxication recipe.~YiQiYangYinFang: Patients with Qi and Yin deficiency syndrome are administered one package of each benefiting Qi and benefiting Yin and two packages of detoxication recipe, four packages, twice a day, until progression or unacceptable.
Study: NCT02889692
Drug: placebo granules
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral granules, which the taste and smell are similar to experimental TCM granules, has no therapeutic effect, four packages, twice a day, until progression or unacceptable.
Study: NCT02367131
Drug: JARDIANCE®
Approvals — FDA: no, EMA: no, PMDA: no
Description: JARDIANCE®
Study: NCT02231164
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: oral placebo
Study: NCT00144131
Drug: Aranesp®
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT03504397
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants received an IV infusion (as a minimum of 2-hour infusion) of placebo matched to zolbetuximab on C1D1 followed by subsequent doses every 3 weeks starting from C1D22 until participant met study treatment discontinuation criteria. Each cycle was approximately 42 days.
Study: NCT03504397
Drug: fluorouracil
Normalized name: Fluorouracil
DrugBank: Fluorouracil (DB00544)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Participants received up to 12 treatments of 5-fluorouracil over 4 or more cycles administered by IV bolus 400 mg/m\^2 over 5 to 15 minutes followed by 2400mg/m\^2 over 46-48 hours continuous IV infusion every 2 weeks for 4 cycles. Participants could continue to receive 5-fluorouracil on Days 1, 15 and 29 of each cycle at the investigator's discretion or until the participant met the study treatment discontinuation criteria. Each cycle was approximately 42 days.
Study: NCT04180215
Drug: HB-201 intravenous administration.
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dose / Schedule determined by 3+3 dose escalation (3 to 6 patients per cohort).
Study: NCT04180215
Drug: HB-202 intravenous administration alternating with HB-201 intravenous administration.
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dose / Schedule determined by 3+3 dose escalation (3 to 6 patients per cohort).
Study: NCT04180215
Drug: HB-201 or HB-201/HB-202 alternating treatment using CD8 PET Tracer (Zr-Df-IAB22M2C)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dose escalation; 10 patients
Study: NCT03566511
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Healthy and T2D participants will receive placebo between baseline MRI scan and second MRI scan.
Study: NCT02741271
Drug: MF/F MDI 100/10 mcg BID
Approvals — FDA: no, EMA: no, PMDA: no
Description: After a 2 week run-in on open-label MF MDI 100 mcg BID, eligible participants will receive double-blinded treatment with MF/F MDI 100/10 mcg BID.
Study: NCT02723994
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT02723994
Drug: Doxorubicin
Normalized name: Doxorubicin
DrugBank: Doxorubicin (DB00997)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT02723994
Drug: Leucovorin Calcium
Normalized name: Leucovorin Calcium
DrugBank: Leucovorin (DB00650)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT02723994
Drug: Mercaptopurine
Normalized name: Mercaptopurine
DrugBank: Mercaptopurine (DB01033)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT02723994
Drug: Methotrexate
Normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT00373685
Drug: Celecoxib
Normalized name: Celecoxib
DrugBank: Celecoxib (DB00482)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: open-label
Study: NCT02570165
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo will be provided as dry white powder for inhalation via a DPI with 30 doses (2 strips with 30 blisters per strip) containing lactose
Study: NCT00668031
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: A loading dose IV infusion of 2,000,000 KIU (200 mL) followed by 500,000 KIU (50 mL) IV per hour until the end of surgery of of placebo using an IV infusion pump
Study: NCT04060862
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Phase 3: Matching placebo, administered PO QD on Days 1-21 of each 28-day cycle at the dose confirmed in the Phase Ib portion.
Study: NCT03307512
Drug: inhaled human insulin
Normalized name: insulin, regular, human Inhalation Powder
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dance 501 (Human Insulin Inhalation Solution and Inhaler) will be administered by inhalation
Study: NCT04735536
Drug: CT1812
Approvals — FDA: no, EMA: no, PMDA: no
Description: Active Treatment- CT1812 at a dose of 300mg
Study: NCT00111878
Drug: MEDI-534
Normalized name: Medi-Lyte
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT04343729
Drug: Placebo solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: injectable saline solution
Study: NCT00689598
Drug: Spironolactone
Normalized name: Spironolactone
DrugBank: Spironolactone (DB00421)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 25 mg po qd 25 mg po bid
Study: NCT00689598
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Spironolactone 25 mg po qd
Study: NCT03300960
Drug: Provera 10 mg.
Approvals — FDA: no, EMA: no, PMDA: no
Description: One 10 mg tablet of MPA (Medroxyprogesterone acetate) is administered every 24 hours from the onset of Controlled Ovarian Stimulation (COS), until the day of triggering.
Study: NCT00455767
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo
Study: NCT00700570
Drug: capecitabine [Xeloda]
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1000mg/m2 iv on days 1-5 and 8-12 of each 2 week cycle
Study: NCT01454115
Drug: Placebo matching BMS-708163
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral Solution, Oral, 0 mg, Once daily, once
Study: NCT01454115
Drug: Placebo matching BMS-708163
Approvals — FDA: no, EMA: no, PMDA: no
Description: Capsule, Oral, 0 mg, Once daily, once
Study: NCT02180269
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single oral dose of placebo matched to JNJ-54861911 on Day 1.
Study: NCT02097043
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00530101
Drug: Doxorubicin
Normalized name: Doxorubicin
DrugBank: Doxorubicin (DB00997)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: This pilot study will select patients who are at increased likelihood to develop cardiotoxicity, due to borderline cardiac function at baseline, advanced age, or the anticipation of a high cumulative dose of administered doxorubicin. Patients who will receive radiation therapy to the left chest during chemotherapy (i.e., left breast cancer) will be excluded so as to eliminate possible cardiotoxic effects from radiation. CMR studies will be performed at no charge to the patient, supported by the sponsor of this study. CMR imaging will be subject to IRB approval, informed consent, and HIPAA regulations. Contrast-enhanced CMR will be obtained at three time points:~Patients will not undergo contrast-enhanced MR unless calculated GFR is equal to or greater than 60 mL/min/1.73 m2
Study: NCT00736879
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tablets, Oral, Once Daily, Up to 24 weeks
Study: NCT02088242
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3 capsules identical in shape, colour and size to the Astaxanthin capsules, which contain only the inactive ingredients of the same formulation.
Study: NCT02004392
Drug: EVP-6124
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02797015
Drug: RPC1063
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral capsule daily
Study: NCT00415350
Drug: Azithromycin
Normalized name: Azithromycin
DrugBank: Azithromycin (DB00207)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Azithromycin Tablet 250 mg daily
Study: NCT02608320
Drug: New JNJ-35685-AAA-G016 (Fentanyl TDS -Small Patches)
Normalized name: fentanyl
DrugBank: Fentanyl (DB00813)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: New JNJ-35685-AAA-G016 12.5 mcg/h (Treatment B) in either period 1, 2 or 3 as per treatment sequence, applied to the paraspinal region of the back for 72 hours.
Study: NCT02042690
Drug: Chemotherapy
Normalized name: Chemotherapy Glove SML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients receive 6 cycles of consolidation chemotherapy after randomization, including Hyper-CVAD-B regimen-Hyper-CVAD-A regimen/Hyper-CVAD-B regimen/Hyper-CVAD-A regimen/Hyper-CVAD-B regimen/Hyper-CVAD-A regimen.Maintenance treatment includes MTX 20mg/m2/w，po，6-mercaptopurine 60 mg/m2/d，po，d1-d28，VP（VDS 4mg,d1, Prednisone 1mg/kg d1-7) every one month for 2 years.
Study: NCT00147251
Drug: FDA approved drugs to treat blood pressure and cholesterol
Normalized name: Cholesterol
DrugBank: Cholesterol (DB04540)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02126371
Drug: LEO32731
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT03771053
Drug: Ezetimibe with simvastatin
Normalized name: ezetimibe / simvastatin
Approvals — FDA: no, EMA: no, PMDA: no
Description: ezetimibe 10mg with simvastatin 40mg everyday for 12 months after PCI
Study: NCT03771053
Drug: Simvastatin
Normalized name: Simvastatin
DrugBank: Simvastatin (DB00641)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: simvastatin 40mg everyday for 12 months after PCI
Study: NCT00267189
Drug: Calcineurin inhibitors (CNI)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02608320
Drug: Aged JNJ-35685-AAA-G016 (Fentanyl TDS Small Patches)
Normalized name: fentanyl
DrugBank: Fentanyl (DB00813)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Aged JNJ-35685-AAA-G016 12.5 mcg/h (Treatment C) in either period 1, 2 or 3 as per treatment sequence, applied to the paraspinal region of the back for 72 hours.
Study: NCT00267189
Drug: Mycophenolate acid (MPA)/ Azathioprine (AZA)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00267189
Drug: Steroids
Normalized name: CORTICOSTEROIDS
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01439568
Drug: LY2510924
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered subcutaneous injection
Study: NCT02608320
Drug: New JNJ-35685-AAA-G021 (Fentanyl TDS Large Patches)
Normalized name: fentanyl
DrugBank: Fentanyl (DB00813)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: New JNJ-35685-AAA-G021 100 mcg/h (Treatment E) in either period 1, 2 or 3 as per treatment sequence, applied to the paraspinal region of the back for 72 hours.
Study: NCT00003254
Drug: ethynyluracil
Normalized name: 5-Ethynyluracil
DrugBank: Eniluracil (DB03516)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10mg/m2/dose, PO, Days 1-28, q 5wk
Study: NCT00003254
Drug: fluorouracil
Normalized name: Fluorouracil
DrugBank: Fluorouracil (DB00544)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 1.0mg/m2/dose, PO, Days 1-28 BID, q 5wk
Study: NCT01632137
Drug: Placebo (vehicle)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Instill one drop into each eye 4 times a day for 4 weeks.
Study: NCT01062048
Drug: Sulfonylurea
Normalized name: Sulfonylurea
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sulfonylurea administered in general use according to the local label
Study: NCT03282851
Drug: MSB11456
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subjects will receive a single injection of MSB11456 on Day 1.
Study: NCT00760448
Drug: insulin NPH
Normalized name: insulin NPH human isophane
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT03970213
Drug: Normal Saline 0.9% Infusion Solution Bag
Approvals — FDA: no, EMA: no, PMDA: no
Description: IV saline given during surgery
Study: NCT03773211
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50 mL added at one occasion ex-vivo to machine perfusion solution to treat kidney at least 3 hours prior to transplantation
Study: NCT02098824
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single administration of capsule containing placebo
Study: NCT03843112
Drug: Vivag Plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Contains two lactobacilli strains; l. gasseri and l. rhamnosus
Study: NCT03843112
Drug: Placebo - Cap
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vaginal supplements
Study: NCT03090009
Drug: Flurbiprofen
Normalized name: Flurbiprofen
DrugBank: Flurbiprofen (DB00712)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 100 mg twice a day for 14 days
Study: NCT03090009
Drug: Placebo Oral Tablet
Normalized name: placebo ORAL TABLET
Approvals — FDA: no, EMA: no, PMDA: no
Description: placebo group
Study: NCT00629772
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients receive placebo on weeks 0, 2 and 6. They receive infliximab 5mg/kg at weeks 14, 16 and 20.
Study: NCT03135626
Drug: Biodentine
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT03135626
Drug: MTA Plus
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02415257
Drug: Gentamicin
Normalized name: Gentamicin
DrugBank: Gentamicin (DB00798)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intratympanic installation of gentamicin 2-4 times depending on the efficacy of vestibular deafferentation
Study: NCT00917111
Drug: Nasal CO2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Four times a day for 14 days
Study: NCT00917111
Drug: Inactive Placebo Gas
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo
Study: NCT02839356
Drug: epinephrine
Normalized name: Epinephrine
DrugBank: Epinephrine (DB00668)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 20-mL irrigation with epinephrine diluted to 0.02% in saline over the entire papilla
Study: NCT02839356
Drug: normal saline
Normalized name: Normal Saline Flush
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20-mL irrigation with physiological saline over the entire papilla
Study: NCT03359239
Drug: Normal saline
Normalized name: Normal Saline Flush
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.19 mL
Study: NCT01131767
Drug: Naproxen Sodium & Pseudoephedrine HCl
Approvals — FDA: no, EMA: no, PMDA: no
Description: Naproxen Sodium 220 mg and Pseudoephedrine Hydrochloride 120 mg Extended Release Tablets
Study: NCT00253760
Drug: dietary amino acids; cysteine and methionine
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00070655
Drug: vitamin K antagonist (warfarin or acenocoumarol) tablets
Normalized name: acenocoumarol
DrugBank: Acenocoumarol (DB01418)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00186329
Drug: Natrecor, a recombinant form of B-type Natriuretic Peptide, made by Scios, Inc. vs. placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02570841
Drug: Topical Placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo exposure within an area of 3x3 cm for 60 minutes
Study: NCT01263704
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 150 milligrams per square meter (mg/m\^2) intravenously (IV) on Days 1-3 of each 28-day cycle for 6 cycles
Study: NCT03866187
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subjects in group A3 receive four doses of placebo, one each at Days 1, 57, 113 and 169 and subjects in group B3 receive two doses of placebo one each at Days 1 and 57, by intramuscular injection in the deltoid of the non-dominant arm. Subjects in group C2 receive 2 co-administered doses of placebo at Days 1 and 57, by intramuscular injection in the deltoid of the dominant and non-dominant arm.
Study: NCT02448628
Drug: CS-3150
Normalized name: MyoGesic-CS
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00445978
Drug: Sapropterin Dihydrochloride
Normalized name: Sapropterin Dihydrochloride
DrugBank: Sapropterin (DB00360)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Subjects will receive oral, once-daily (for 2.5, 5, 10mg/kg/day doses) or twice-daily (for the 20 mg/kg/day dose) sapropterin dihydrochloride during a 16-week dose escalation phase, with dose levels increasing within subjects every 4 weeks as follows: 2.5, 5, 10, and 20 mg/kg/day. Dosing was with 100 mg tablets and rounded to the nearest whole tablet. Each dose was taken within 1 hour after the morning meal. Subjects may continue in an optional extension phase at the highest tolerated dose for up to a total of 2 years.
Study: NCT01502280
Drug: Placebo - ascorbic acid
Approvals — FDA: no, EMA: no, PMDA: no
Description: Within 3 hours prior to surgery, patient will orally ingest \[or be given via Nasogastric (NG), Orogastric (OG), or Gastric tube (G-tube)\] 1.5 Gm. placebo - ascorbic acid in 50 ml sterile water.
Study: NCT04568993
Drug: Volar to the MCP-joint
Normalized name: ActivOn Joint & Muscle
Approvals — FDA: no, EMA: no, PMDA: no
Description: Injection of methyl prednisone and lidocaine in the tendon sheet volar to the MCP-joint
Study: NCT04068610
Drug: FOLFOX
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants will receive IV infusion of FOLFOX (5-FU, oxaliplatin, and folinic acid) as stated in arm description.
Study: NCT01163266
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vortioxetine placebo-matching capsules
Study: NCT00565370
Drug: Capecitabine, Cisplatin, Sorafenib
Approvals — FDA: no, EMA: no, PMDA: no
Description: Capecitabine ( ) mg/m2 bid D1-D15 Cisplatin 80 mg/m2 D1 Sorafenib ( ) mg bid PO daily every 3 weeks
Study: NCT02752204
Drug: AZD 2014
Normalized name: aspirin / hydrocodone bitartrate Oral Tablet [Azdone]
Approvals — FDA: no, EMA: no, PMDA: no
Description: AZD2014 125mg BD - 2 days on 5 days off in a 28 day cycle
Study: NCT01712230
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo
Study: NCT00773526
Drug: RO5126766
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered orally daily for 28 days, at escalating doses (with a starting dose of 0.1mg) (Part 1). Optimal biological dose or maximum tolerated dose administered orally, daily (Part 2).
Study: NCT00647166
Drug: corticosteroid and azathioprine
Normalized name: Azathioprine
DrugBank: Azathioprine (DB00993)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: * Corticosteroid 1 mg/kg/day with a conventional decrease dose~* Azathioprine : 2 mg/kg/day during one year in 2 to 3 times a day by oral route
Study: NCT03295058
Drug: Non ATG Conditioning regimen
Normalized name: Anacin Aspirin Regimen
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50% of the patients will receive Fludarabine + cyclophosphamide (F-araA 120 mg/m2 total dose for 3 days (d-3,-2,-1) over 1 h infusion and cyclophosphamide 25 mg/kg/d (d-5 to d-2) for 4 days over 1-h infusion prior to hematopoietic cell transplantation , then post transplant cyclophosphamide dose 50 mg/kg on days +3 and +4
Study: NCT03295058
Drug: ATG conditioning regimen
Normalized name: Anacin Aspirin Regimen Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: the other 50% of the patients will receive Cyclophosphamide + ATG
Study: NCT04399837
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Solution for injection
Study: NCT03472872
Drug: Ketorolac
Normalized name: Ketorolac
DrugBank: Ketorolac (DB00465)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 15mg ketorolac in 100mL 0.9% normal saline IVPB 1,000mg acetaminophen in a 100ml IVPB
Study: NCT03472872
Drug: Acetaminophen
Normalized name: Acetaminophen
DrugBank: Acetaminophen (DB00316)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1,000mg acetaminophen IVPB
Study: NCT02182258
Drug: BIBF 1120 intravenous solution
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02182258
Drug: Placebo ampoule
Approvals — FDA: no, EMA: no, PMDA: no